InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $9.2M-23.1% | $11.9M-19.7% | $14.8M-16.1% | $17.7M |
| General and administrative | $18.5M+1.6% | $18.2M+19.3% | $15.3M+30.1% | $11.8M |
| Stock-based compensation – general and administrative | $10.8M-8.5% | $11.8M+78.9% | $6.6M+69.4% | $3.9M |
| Total Operating Expenses | $38.5M-8.3% | $42.0M+14.3% | $36.7M+10.3% | $33.3M |
| Operating Loss | -$38.5M+8.3% | -$42.0M-14.3% | -$36.7M-10.3% | -$33.3M |
| Interest income | $110K-85.5% | $758K-35.7% | $1.2M+369.1% | $251K |
| Interest expense | -$268K | — | — | — |
| Gain on sale of New Jersey net operating losses | $2.4M | — | $3.6M | — |
| Total Other Income (Expense), Net | -$158K-105.0% | $3.1M-34.0% | $4.8M+1795.4% | $251K |
| Loss before Income Taxes | -$38.7M+0.4% | -$38.8M-21.5% | -$32.0M+3.3% | -$33.1M |
| Income tax expense | $1.1M+83.5% | $576K+0.0% | $576K+0.0% | $576K |
| Net Loss | -$39.7M-0.8% | -$39.4M-21.2% | -$32.5M+3.3% | -$33.6M |
| Net loss attributable to non-controlling interest | $2.3M+703.6% | $287K | — | — |
| Deemed dividend on warrant extension | -$1.0M | — | -$1.2M | — |
| Net Loss Applicable to Common Stockholders | -$37.4M+6.8% | -$40.2M-19.3% | -$33.7M-0.2% | -$33.6M |
| Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share) | -$3.38+43.4% | -$5.97-7.2% | -$5.57-2321.7% | -$0.23 |
| Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share) | -$3.38+43.4% | -$5.97-7.2% | -$5.57 | — |
| Basic (in Shares) | $11.1M+64.5% | $6.7M+11.2% | $6.1M-95.9% | $146.1M |
| Diluted (in Shares) | $11.1M+64.5% | $6.7M+11.2% | $6.1M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
Citius Pharmaceuticals GAAP EPS of -$0.95, revenue of $1.7M
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update